Globalinternet: “Now is the Time to Rethink Your Sourcing Strategy for Network Connectivity”
5.10.2020 15:00:00 EEST | Business Wire | Press release
Globalinternet, the Amsterdam-headquartered company that provides connectivity for more than 600 enterprises globally, today releases a white paper on what they call the ‘Accelerated Internet Shift’. The white paper focuses on the accelerating shift from private to public networks, including the impact of COVID-19 on large corporations that had to rethink their entire operational practices while employees were forced to work from home.
The white paper, commissioned in partnership with research consultancy Omdia, is a comprehensive tool for CIOs and IT executives around the world to get the latest insights regarding internet connectivity during the current pandemic and beyond. It underlines the importance for enterprises to prioritise network transformation projects and so becoming resilient in a post-COVID / Work-from-home world.
The research shows that existing global network service providers are a known quantity but more and more enterprises are looking for new suppliers to source their network services as a way to get fresh perspectives and more competitive solutions. For example: no less than 49% of enterprises turned to new network providers when adopting SD-WAN, and more than one-third of large enterprises expect to re-reconsider their primary network partner.
“The shift from private to public networks was a trend that was on our radar for a long time,” says Kees Bos, CEO Globalinternet. “But the big news is that this is accelerating at a high speed. Enterprises have felt the first shock from COVID and, despite needing to cut budgets for the foreseeable future, these enterprises are prioritizing the shift to internet and SD-WAN. They realize that money spent today on these network enhancements will help the company be nimbler and in a stronger position tomorrow”
The full white paper can be downloaded here.
About Globalinternet
Globalinternet is a leading provider for business-grade internet connectivity – anywhere on the planet. We partner with brilliant local Internet Service Providers and technology partners in 190+ countries to offer a best-in-class product portfolio with an unparalleled range of dedicated, broadband and mobile internet access services, coupled with around-the-clock assurance and support.
Founded in 2012, Globalinternet has worked since with more than 600 enterprises, delivering the underlay to enable their network transformation projects. Customers can monitor and manage their diverse internet services through the GINius customer portal. The portal supports APIs for fully automated integration with enterprises’ internal systems allowing them to take control of their internet underlay. For more information: www.globalinter.net
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005412/en/
Contact information
Press Contacts
Daniela Muente
Head of Global Marketing
Daniela.Muente@Globalinter.net
+31 654355430
Linda Roemer
Marketing Manager
Linda.Roemer@Globalinter.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom